A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer

M Ueno, T Okusaka, Y Omuro, H Isayama, A Fukutomi, M Ikeda, N Mizuno, K Fukuzawa, M Furukawa, H Iguchi, K Sugimori, J Furuse, K Shimada, T Ioka, S Nakamori, H Baba, Y Komatsu, M Takeuchi, I Hyodo, N Boku, M Ueno, T Okusaka, Y Omuro, H Isayama, A Fukutomi, M Ikeda, N Mizuno, K Fukuzawa, M Furukawa, H Iguchi, K Sugimori, J Furuse, K Shimada, T Ioka, S Nakamori, H Baba, Y Komatsu, M Takeuchi, I Hyodo, N Boku

Abstract

Background: We evaluated the efficacy and toxicity of adding oral leucovorin (LV) to S-1 when compared with S-1 monotherapy in patients with gemcitabine-refractory pancreatic cancer (PC).

Patients and methods: Gemcitabine-refractory PC patients were randomly assigned in a 1:1 ratio to receive S-1 at 40, 50, or 60 mg according to body surface area plus LV 25 mg, both given orally twice daily for 1 week, repeated every 2 weeks (SL group), or S-1 monotherapy at the same dose as the SL group for 4 weeks, repeated every 6 weeks (S-1 group). The primary end point was progression-free survival (PFS).

Results: Among 142 patients enrolled, 140 were eligible for efficacy assessment (SL: n = 69 and S-1: n = 71). PFS was significantly longer in the SL group than in the S-1 group [median PFS, 3.8 versus 2.7 months; hazard ratio (HR), 0.56; 95% confidence interval (CI), 0.37-0.85; P = 0.003]). The disease control rate was significantly higher in the SL group than in the S-1 group (91% versus 72%; P = 0.004). Overall survival (OS) was similar in both groups (median OS, 6.3 versus 6.1 months; HR, 0.82; 95% CI, 0.54-1.22; P = 0.463). After adjusting for patient background factors in a multivariate analysis, OS tended to be better in the SL group (HR, 0.71; 95% CI, 0.47-1.07; P = 0.099). Both treatments were well tolerated, although gastrointestinal toxicities were slightly more severe in the SL group.

Conclusion: The addition of LV to S-1 significantly improved PFS in patients with gemcitabine-refractory advanced PC, and a phase III trial has been initiated in a similar setting.

Clinical trials number: Japan Pharmaceutical Information Center: JapicCTI-111554.

Keywords: S-1; albumin; gemcitabine-refractory pancreatic cancer; leucovorin; pancreatic resection; phase II study.

© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology.

Figures

Figure 1.
Figure 1.
Kaplan–Meier curves of (A) progression-free survival (assessed by independent review committee) and (B) overall survival.

References

    1. Jemal A, Bray F, Center MM et al. . Global cancer statistics. CA Cancer J Clin 2011; 61: 69–90.
    1. Conroy T, Desseigne F, Ychou M et al. . FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817–1825.
    1. Von Hoff DD, Ervin T, Arena FP et al. . Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369: 1691–1703.
    1. Oettle H, Riess H, Stieler JM et al. . Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol 2014; 32: 2423–2429.
    1. Ueno H, Ioka T, Ikeda M et al. . Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol 2013; 31: 1640–1648.
    1. Morizane C, Okusaka T, Furuse J et al. . A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol 2009; 63: 313–319.
    1. Ohkawa S, Okusaka T, Isayama H et al. . Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer. Br J Cancer 2015; 112: 1428–1434.
    1. Mizuno N, Yamao K, Komatsu Y et al. . Randomized phase II trial of S-1 versus S-1 plus irinotecan (IRIS) in patients with gemcitabine-refractory pancreatic cancer. In J Clin Oncol 2013; 31 (Suppl. 4); abstr 263.
    1. Thirion P, Michiels S, Pignon JP et al. . Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004; 22: 3766–3775.
    1. Tsukioka S, Uchida J, Tsujimoto H et al. . Oral fluoropyrimidine S-1 combined with leucovorin is a promising therapy for colorectal cancer: evidence from a xenograft model of folate-depleted mice. Mol Med Rep 2009; 2: 393–398.
    1. Van Cutsem E, Findlay M, Osterwalder B et al. . Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol 2000; 18: 1337–1345.
    1. Koizumi W, Boku N, Yamaguchi K et al. . Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer. Ann Oncol 2010; 21: 766–771.
    1. Denda T, Li J, Xu R et al. . Phase II study of S-1 plus leucovorin (a new 1-week treatment regimen followed by a 1-week rest period) in patients with untreated metastatic colorectal cancer in Japan and China. J Clin Oncol 2012; 30 (Suppl. 4): abstr 598.
    1. Hironaka S, Sugimoto N, Yamaguchi K et al. S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial. Lancet Oncol 2016; 17: 99–108
    1. Wang-Gillam A, Li CP, Bodoky G et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 2015 Nov 29 [epub ahead of print], .
    1. Rahma OE, Duffy A, Liewehr DJ et al. . Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. Ann Oncol 2013; 24: 1972–1979.
    1. Prado CM, Baracos VE, McCargar LJ et al. . Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 2009; 15: 2920–2926.
    1. Baumgartner RN, Koehler KM, Romero L, Garry PJ. Serum albumin is associated with skeletal muscle in elderly men and women. Am J Clin Nutr 1996; 64: 552–558.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera